Stock·NYSE·Financial Services
Marsh McLennan (MRSH)
- Market cap
- $90.68B
- P/E
- 22.76
- Dividend yield
- 1.98%
- Street target
- $201.00median of 23 analysts
- 52-week range
- $156.60 $200.33
MRSH stock forecast today
Where MRSH stands today, and what CleaRank Financial AI makes of it.
MRSH at a glance
Marsh McLennan (MRSH): Buy, 69/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($181.86 and $176.98).
- Earnings MRSH beat estimates in 7 of the 7 reports in our data, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $28.1M and bought $202K over the last 18 months.
- Valuation P/E of 22.8 against 16.5 for the Financial Services sector: a premium to peers (+38%).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Marsh McLennan (MRSH) Buy, with a model score of 69/100.
The trend lifts the score most: the price is 7.75% above its 200-day average and 4.86% above its 50-day average, and the 50-day average is 2.76% above the 200-day. Valuation holds it back most: the P/E of 22.76 is 38.0% above the sector median (a premium to peers). The 50-day average stands at $181.86 and the 200-day at $176.98. Over the past year the price rose 1.64%.
Only on CleaRank
Figures we compute ourselves from MRSH's own price, earnings and insider-filing history. Tap one to see it in context.
MRSH stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $190.70 is 4.9% above the 50-day simple moving average of $181.86.Price above its 200-day average ›
The price is 7.8% above the 200-day simple moving average of $176.98.50-day average above the 200-day ›
The 50-day average ($181.86) is 2.8% above the 200-day average ($176.98), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 78% of its 52-week range, between $156.60 and $200.33.
MRSH share price
Pick a period: each tab shows how far MRSH has moved over it, to the last close.
Today's trading
Where MRSH sits inside today's range and its 52-week range.
MRSH fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 22.76 is 38.0% above the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 3.18 is 16.3% below the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $4.0B on revenue of $28.5B, a net margin of 14.2%.Beat estimates in most recent reports ›
MRSH beat the EPS estimate in 7 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 1.98%, or $3.78 a share a year.
Key statistics
The headline figures for MRSH.
As of October 27, 2026, MRSH trades at $190.70, with a market value of $90.68B, a P/E ratio of 22.76 and a dividend yield of 1.98%.
What the numbers say
CleaRank Financial AI's reading of MRSH's valuation, growth and risks.
Against the 16.5 median P/E of Financial Services stocks, Marsh McLennan (MRSH)'s P/E of 22.76 is 38.0% above that median, which counts as a premium to peers. The price-to-sales ratio of 3.18 sits 16.3% below the sector median of 3.8. The company has a market capitalisation of $90.7B.
MRSH is growing more slowly than its sector. Profitability is solid: a net margin of 14.20% and an operating margin of 18.40% sit alongside a return on equity of 27.24%, which is above the sector median of 13.8%. On the balance sheet, debt-to-equity stands at 1.50, and the trailing dividend yield is 1.98%, equal to $3.78 a share each year.
MRSH beat the estimate by 3.05% in its most recent report, dated October 15, 2026. Reported EPS was $2.03 against an estimate of $1.97. The share price rose 0.97% in the session after the report.
The record is a clean sweep: 7 beats in 7 reports; even so, 4 of those 7 beats were followed by a lower share price the next session. Analysts' average EPS estimate for this fiscal year is $10.48, which would be growth of 7.5%, and $11.45 for next year (growth of 9.3%).
A P/E of 22.76 sits 38.0% above the sector median, which makes MRSH a premium to peers, so future results may need to clear a higher bar. The first thing to plan around is day-to-day movement: the stock has moved 1.51% on an average session, and its beta against the S&P 500 is 0.59. Insiders sold $28.1M of stock over the last 18 months and bought $202K. Sales like these are often planned in advance, so they tell less than purchases would.
MRSH against the Financial Services sector
How MRSH compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: MRSH trades at a significant premium to sector peers (+38%), suggesting market expectations for superior growth or market position.
Return vs XLF: Since May 15, 2025, MRSH has lost 16.1% against a gain of 9.0% for XLF.
Performance against XLF
MRSH and the Financial Services sector fund over the same days.
Revenue and earnings
How much MRSH sells, and how much of it becomes profit.
The quarterly bars end with Q4 '25 (the quarter to December 31, 2025); MRSH reported again on October 15, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 10.3% in FY2025 to $27.0B, from $24.5B a year earlier.
Profit margin: The net margin was 15.7% in FY2025, down from 16.8% the year before.
Profitable: MRSH earned $4.2B in FY2025.
Earnings reality check
Did MRSH beat what analysts expected, and how did the stock react?
Earnings record: MRSH beat the analyst estimate in 7 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 4 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 15, 2026after close | $1.97 | $2.03 | +3.05% | +0.97% | +6.82% |
| Jul 21, 2026after close | $2.89 | $2.96 | +2.42% | -3.08% | +5.84% |
| Apr 16, 2026after close | $3.22 | $3.29 | +2.17% | -3.71% | -4.69% |
| Oct 16, 2025after close | $1.78 | $1.85 | +3.93% | +1.67% | +0.86% |
| Jul 17, 2025after close | $2.66 | $2.72 | +2.26% | +0.59% | -1.29% |
| Apr 17, 2025after close | $3.00 | $3.06 | +2.00% | -3.62% | -0.38% |
| Jan 30, 2025after close | $1.76 | $1.87 | +6.25% | -1.79% | +2.34% |
As of October 27, 2026, MRSH has beaten the analyst EPS estimate in 7 of the 7 reports in our data and fell in the first trading session after 4 of those beats; its latest report, on October 15, 2026, came in 3.05% above the estimate and the stock moved +0.97% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
MRSH AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 60.7, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 60.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of MRSH
The score, the reasoning behind it, and what could move the price next.
Marsh McLennan (MRSH) is in an uptrend by the usual test: both averages sit below the price. At $190.70, the stock trades 4.86% above its 50-day average of $181.86 and 7.75% above its 200-day average of $176.98. The price is near the top of its 52-week range, 4.81% below the high of $200.33 and 21.78% above the low of $156.60. The 50-day average also sits 2.76% above the 200-day, so the two averages point the same way.
The 14-day RSI of 60.7 is in the bullish zone, below the overbought line, and the MACD line is positive. The short and long run point different ways: the price rose 11.44% over the past month, fell 0.78% over the past three months and rose 1.64% over the past year.
Earnings beat ›
The October 15, 2026 report beat the EPS estimate by 3.05%, and the share price rose 0.97% in the first session after it.
Source: Earnings report, October 15, 2026Rating reaffirmed ›
JP Morgan kept its Overweight rating on October 20, 2026.
Source: Analyst action, JP Morgan, October 20, 2026
- Two levels matter most right now: the 52-week high at $200.33, which sits above the price, and the 20-day EMA at $185.51, which sits below it.
- The 14-day RSI reads 60.7, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price rose 0.97% in the first session after the October 15, 2026 report. Over the 7 reports in our data, MRSH beat estimates in 7 of them.
The uptrend rests on MRSH staying above its 50-day average at $181.86 and its 200-day average at $176.98; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $185.51.
The 52-week high at $200.33 is the next level overhead. Momentum, with the RSI in the bullish zone, still backs the move.
Technical indicators
Momentum and trend for MRSH, from its daily closes.
As of October 27, 2026, with MRSH at $190.70, its 14-day RSI is 60.7 (showing bullish momentum without being overbought), its 50-day simple moving average is $181.86 and its 200-day is $176.98.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What MRSH moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, MRSH's 1-year correlation of daily returns is +0.11 with S&P 500 (SPY), -0.06 with Nasdaq 100 (QQQ), -0.06 with Bitcoin (BTC) and -0.14 with gold (XAU).
MRSH price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
7 of 23 analysts rate it a buy or strong buy, 15 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $201.00 is 5.4% above the price.More buy ratings than three months ago ›
7 of 23 rate it a buy now, against 7 of 23 three months ago.
MRSH Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 20, 2026 | JP Morgan | Maintains | Overweight |
| Oct 19, 2026 | Mizuho | Maintains | Neutral |
| Oct 19, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform |
| Oct 16, 2026 | Citigroup | Maintains | Neutral |
| Oct 16, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Oct 12, 2026 | Wells Fargo | Maintains | Equal-Weight |
As of October 27, 2026, 23 Wall Street analysts cover MRSH: 7 rate it a buy or strong buy, 15 a hold and 1 a sell or strong sell. Their 12-month price targets range from $180.00 to $228.00. The median MRSH price target is $201.00, 5.4% above the price of $190.70.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
MRSH trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MRSH trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from MRSH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MRSH tends to move, against the market and on its own.
MRSH price history and drawdowns
MRSH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.51% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 31.9%, from March 2025 to June 2026; the price is still 18.6% below that peak.Most 1-year holds ended higher ›
81% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $36,485, against $42,015 in the S&P 500 (SPY).
MRSH Drawdowns & Recovery
As of October 27, 2026, MRSH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -31.9% (March 2025 to June 2026); it is still 18.6% below that peak, and 81% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MRSH in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: MRSH trailed the S&P 500 over this period: $36,485 against $42,015.
A $10,000 investment in MRSH in October 2016 would be worth about $36,485 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MRSH, and which have not.
Strongest month, November: an average of +4.81%, up in 9 of 10 years.
Weakest month, December: an average of -2.12%, up in 4 of 10 years.
This month, October: has averaged -0.71%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, MRSH's strongest calendar month has been November (average +4.81%, up in 9 of 10 years) and its weakest December (average -2.12%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
MRSH stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MRSH, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in MRSH today could grow to about $13,798 by 2030 in the base case, with a 90th-percentile outcome near $23,861 and a 10th-percentile outcome around $7,979. The simulation models price only; at today's 1.98% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
MRSH Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $263 for MRSH by 2030 in the base case, from $191 today (1.4x over 4 years). The 10th-percentile path ends near $152. These are outcomes of a Monte Carlo simulation run on MRSH's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $157 | $207 | $272 | |
| 2028 | $152 | $224 | $330 | |
| 2029 | $151 | $243 | $390 | |
| 2030 | $152 | $263 | $455 |
Method: a lognormal simulation of MRSH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
MRSH insider trading
What the people running the company have bought and sold.
MRSH insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $202K on the open market and sold $28.1M.
As of October 27, 2026, MRSH insiders reported 13 open-market sales worth $28.1M and 1 open-market purchase worth $202K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | John Q Doyle
Chief Executive Officer
|
Sell | 16.7K | $3.1M |
| Sep 2, 2026 | Katherine J. Brennan
General Counsel
|
Sell | 1.2K | $224.9K |
| Sep 2, 2026 | Katherine J. Brennan
General Counsel
|
Option | 1.2K | $99.4K |
| Sep 2, 2026 | John Q Doyle
Chief Executive Officer
|
Option | 16.7K | $1.2M |
| Aug 14, 2026 | Bruce D. Broussard
Director
|
Grant | 192 | $36.2K |
| Aug 14, 2026 | Steven A Mills
Director
|
Grant | 194 | $36.6K |
| Aug 6, 2026 | John Jude Jones
Officer
|
Sell | 6.5K | $1.2M |
| Jul 29, 2026 | Paul Beswick
Chief Technology Officer
|
Sell | 713 | $141.2K |
| Jul 28, 2026 | Martin South
Officer
|
Sell | 7.1K | $1.3M |
| Jul 23, 2026 | Lloyd M Yates
Director
|
Sell | 12.0K | $2.1M |
| Jun 2, 2026 | John Q Doyle
Chief Executive Officer
|
Sell | 16.7K | $2.7M |
| Jun 2, 2026 | John Q Doyle
Chief Executive Officer
|
Option | 16.7K | $1.2M |
| Jun 1, 2026 | Bruce D. Broussard
Director
|
Grant | 1.3K | $214.9K |
| Jun 1, 2026 | H Edward Hanway
Director
|
Grant | 1.3K | $214.9K |
| Jun 1, 2026 | Peter Harrison
Director
|
Grant | 1.3K | $215.0K |
| Jun 1, 2026 | Judith Hartmann
Director
|
Grant | 1.3K | $214.9K |
| Jun 1, 2026 | Steven A Mills
Director
|
Grant | 1.3K | $214.9K |
| May 15, 2026 | Steven A Mills
Director
|
Grant | 264 | $42.4K |
| Mar 13, 2026 | Patrick Tomlinson
Officer
|
Grant | 1.2K | - |
| Mar 11, 2026 | John Jude Jones
Officer
|
Sell | 2.4K | $410.1K |
| Mar 4, 2026 | John Q Doyle
Chief Executive Officer
|
Sell | 16.7K | $3.1M |
| Mar 4, 2026 | John Q Doyle
Chief Executive Officer
|
Grant | 16.7K | - |
| Mar 3, 2026 | Nicholas Mark Studer
Officer
|
Sell | 3.8K | $706.1K |
| Feb 27, 2026 | Paul Beswick
Chief Technology Officer
|
Grant | 7.0K | - |
| Feb 27, 2026 | Katherine J. Brennan
General Counsel
|
Grant | 7.0K | - |
| Feb 27, 2026 | John Q Doyle
Chief Executive Officer
|
Grant | 59.5K | - |
| Feb 27, 2026 | Carmen Fernandez
Officer
|
Grant | 7.0K | - |
| Feb 27, 2026 | John Jude Jones
Officer
|
Grant | 4.8K | - |
| Feb 27, 2026 | Dean Michael Klisura
Officer
|
Grant | 9.4K | - |
| Feb 27, 2026 | Mark C Mcgivney
Chief Financial Officer
|
Grant | 18.0K | - |
| Feb 27, 2026 | Stacy Mills
Officer
|
Grant | 2.7K | - |
| Feb 27, 2026 | Martin South
Chief Executive Officer
|
Grant | 14.5K | - |
| Feb 27, 2026 | Nicholas Mark Studer
Chief Executive Officer
|
Grant | 8.0K | - |
| Feb 27, 2026 | Patrick Tomlinson
Officer
|
Grant | 2.2K | - |
| Feb 13, 2026 | Steven A Mills
Director
|
Grant | 244 | $42.3K |
| Dec 1, 2025 | John Q Doyle
Chief Executive Officer
|
Sell | 21.1K | $3.8M |
| Dec 1, 2025 | John Q Doyle
Chief Executive Officer
|
Option | 21.1K | $1.3M |
| Nov 14, 2025 | Steven A Mills
Director
|
Grant | 231 | $42.3K |
| Sep 2, 2025 | John Q Doyle
Chief Executive Officer
|
Sell | 21.1K | $4.3M |
| Sep 2, 2025 | John Q Doyle
Chief Executive Officer
|
Option | 21.1K | $1.3M |
| Aug 15, 2025 | Steven A Mills
Director
|
Grant | 204 | $42.4K |
| Jul 30, 2025 | Anthony K Anderson
Director
|
Buy | 1.0K | $201.6K |
| Jun 2, 2025 | John Q Doyle
Chief Executive Officer
|
Sell | 21.1K | $4.9M |
| Jun 2, 2025 | John Q Doyle
Chief Executive Officer
|
Option | 21.1K | $1.3M |
| May 30, 2025 | H Edward Hanway
Director
|
Grant | 929 | $214.9K |
| May 30, 2025 | Judith Hartmann
Director
|
Grant | 929 | $214.9K |
| May 30, 2025 | Steven A Mills
Director
|
Grant | 929 | $214.9K |
| May 20, 2025 | Stacy Mills
Officer
|
Grant | 218 | - |
| May 15, 2025 | Oscar Martin Fanjul
Director
|
Grant | 157 | $35.0K |
| May 15, 2025 | Steven A Mills
Director
|
Grant | 185 | $41.1K |
Source: TwelveData, from SEC Form 4 filings
MRSH stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.